Angela Sacchinelli

article 2015

Evaluating CA125 and VAS Pain Modifications following Gnrh Analog to Exclude Superficial Endometriosis as Cause of Chronic Pelvic Pain

·doi:10.5301/je.5000205

Background The study aim was to assess the reliability in the diagnosis of superficial endometriosis of the combined evaluation of 2 parameters: modifications of serum CA125 and VAS pain score following 1 dose of GnRH analog (GnRH-a). Metho…

article 2014

CA125 and VAS Pain Score Modifications Following GnRH-Analog Administration as Ex Adiuvantibus Criteria to Diagnose Endometriosis as Cause of Chronic Pelvic Pain

·doi:10.1016/j.jmig.2014.08.457

article 2014

Periostin Expression Is Related to the Invasive Tumor-Like Phenotype of Endometriosis: A New Promising Biomarker to Use in Risk Stratification of Patients

·doi:10.1016/j.jmig.2014.08.058

article 2013

Postoperative administration of dienogest plus estradiol valerate versus levonorgestrel‐releasing intrauterine device for prevention of pain relapse and disease recurrence in endometriosis patients

Journal of Obstetrics and Gynaecology Research ·doi:10.1111/jog.12030

AIM: In recent years, both dienogest, a fourth-generation progestin, and levonorgestrel-releasing intrauterine device have been found to be effective in terms of endometriosis-related pelvic pain improvement. No data, however, are available…

article 2009

Continuous Versus Cyclic Postoperative Use of Low-Dose Combined Oral Contraceptive Belara® for the Treatment of Endometriosis-Related Chronic Pelvic Pain

·doi:10.1016/j.jmig.2009.08.416